GILD - Gilead Sciences, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
79.95
-1.22 (-1.50%)
At close: 4:00PM EDT

79.95 0.00 (0.00%)
After hours: 5:51PM EDT

Stock chart is not supported by your current browser
Previous close81.17
Open81.13
Bid79.92 x 300
Ask79.99 x 6700
Day's range79.55 - 81.21
52-week range63.76 - 86.27
Volume6,787,274
Avg. volume9,354,725
Market cap104.41B
Beta0.90
PE ratio (TTM)8.68
EPS (TTM)N/A
Earnings dateN/A
Dividend & yield2.08 (2.56%)
Ex-dividend date2017-09-14
1y target estN/A
Trade prices are not sourced from all markets
  • Barrons.com6 hours ago

    [$$] More Biotechs That Can Beat Q3 Views

    Credit Suisse Overall, we think most U.S. biotech companies look to be in-line-to-above consensus estimates. Where we have conviction and are focused into quarter: We think Biogen (BIIB) has potential to beat based mostly on Spinraza U.S. trends after reviewing a recent slide deck from the CureSMA website.

  • Forbes6 hours ago

    Berkshire Hathaway And 6 Other Piggyback Stocks To Profit From

    Seven buy list stocks from some of the greatest value investors.

  • The Zacks Analyst Blog Highlights: NIKE, Cisco Systems, Gilead Sciences, Las Vegas Sands and Aon
    Zacks8 hours ago

    The Zacks Analyst Blog Highlights: NIKE, Cisco Systems, Gilead Sciences, Las Vegas Sands and Aon

    The Zacks Analyst Blog Highlights: NIKE, Cisco Systems, Gilead Sciences, Las Vegas Sands and Aon

  • 6 Top Biotech Companies In Innovation Earn Recognition In New Awards
    Investor's Business Daily10 hours ago

    6 Top Biotech Companies In Innovation Earn Recognition In New Awards

    Cancer. Alzheimer’s. MS. Treatments from the fast-growing U.S. biotech industry provide new hope for patients. What are the top biotech companies in innovation?

  • Kite Pharma Cancer Treatment Stands Out In Hot CAR-T Field
    Investor's Business Daily10 hours ago

    Kite Pharma Cancer Treatment Stands Out In Hot CAR-T Field

    Gilead's new Kite Pharma unit is a leader in cutting-edge CAR-T therapy that fights cancer by rebuilding a patient's cells. Here's how its treatment stands out and who it helps.

  • The Wall Street Journal19 hours ago

    [$$] Nimbus Therapeutics Strikes Immunology Deal With Celgene

    Nimbus Therapeutics, which struck a $1.2 billion deal to sell a drug program focused on liver diseases to Gilead Sciences Inc. last year, has formed a new immunology collaboration with Celgene Corp.

  • Top Stock Reports for NIKE, Cisco Systems & Gilead Sciences
    Zacks3 days ago

    Top Stock Reports for NIKE, Cisco Systems & Gilead Sciences

    Top Stock Reports for NIKE, Cisco Systems & Gilead Sciences

  • 3 Healthcare Value Stocks
    Motley Fool3 days ago

    3 Healthcare Value Stocks

    Looking for some investments in the healthcare sector that aren't priced at a high premium? Allergan, Gilead Sciences, and DaVita are an excellent place to start.

  • Non-Alcoholic Steatohepatitis 2017 Progress Update
    Zacks4 days ago

    Non-Alcoholic Steatohepatitis 2017 Progress Update

    Bigwigs of late have been investing a substantial portion of their R&D sources for the treatment of Non-Alcoholic Steatohepatitis (NASH).

  • Reuters - UK Focus4 days ago

    US NIH, 11 drugmakers partner to accelerate cancer therapy research

    The Trump Administration threw its support behind a public-private partnership with 11 drug companies to advance a new class of drugs that uses the body's immune system to fight cancer. The five-year collaboration ...

  • 5 Game-Changing Cancer Drug Innovations Being Developed Right Now
    Motley Fool4 days ago

    5 Game-Changing Cancer Drug Innovations Being Developed Right Now

    Could these revolutionary therapies turn the tide in the fight against cancer?

  • Motley Fool5 days ago

    Is AbbVie the Best Dividend Stock in Healthcare?

    AbbVie's yield is higher than those of its peers, but expiring patents on the company's top-selling drug does make it a bit riskier than other dividend payers in healthcare.

  • Here's What's Has Happened in the HCV Space Lately
    Zacks10 days ago

    Here's What's Has Happened in the HCV Space Lately

    A lot has happened in the hepatitis C virus space of late. The market is getting crowded and seeing increased pricing pressure.

  • Barrons.com10 days ago

    Gilead Sciences & AbbVie: Mother Always Told Me to Share

    Leerink's Geoffrey Porges  and Bradley Canino recently reviewed the Hepatitis C (HCV) market, and increased their price targets on Gilead (GILD) and AbbVie (ABBV) They write that both stocks are likely to enjoy a duopoly for HCV "in perpetuity," as other competitors like Bristol Myers Squibb (BMY), Johnson & Johnson (JNJ) and Merck (MRK) have scaled back their efforts. More from the note: After the recent announcements from JNJ (returning the rights to Achillion’s [ACHN] HCV NS5a inhibitor) and Merck (halting further development of uprifosbuvir), and the prior discontinuation of further investment into HCV at Bristol Myers after their unsuccessful investment into Inhibitex, it is now clear that the HCV category will come down to only two committed participants, Gilead and AbbVie.

  • Barrons.com11 days ago

    Gilead Sciences: How You'll Know It's Time to Buy

    Gilead Sciences (GILD) entered the year on a downswing, but its stock has since reversed that underperformance and now sits near a 52-week high. It's not that much has changed: Hepatitis C is still a big question mark and its HIV business could be threatened by competition. Oppenheimer's Hartaj Singh and Emma Nealon liken Gilead Sciences to a supertanker trying to accelerate.

  • Forbes12 days ago

    Cancer-Cure Makers Make Great Takeover Stocks

    This company's impressive technology portfolio make it a great acquisition candidate.

  • Barrons.com12 days ago

    Gilead Sciences: Better Safe Than…Not Working At All

    Today, Gilead Sciences (GILD) announced that a Phase 3 trial of switching to Bictegravir-F-Taf for HIV patients was completed with positive safety results, following a July announcement about data that demonstrated that it didn't work better than what its intended to replace. In a press release, Gilead explains why it considers the results a big deal: “These data demonstrate the potential of BIC/FTC/TAF to match the efficacy of a boosted protease inhibitor regimen while also offering a high barrier to resistance and fewer interactions with other drugs,” said Eric Daar, MD, Chief of the Division of HIV Medicine at Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center and lead author of Study 1878. “The findings, along with data from three other Phase 3 studies in both treatment-experienced and treatment-naïve patients, suggest that the investigational regimen of BIC/FTC/TAF may be appropriate for a broad range of people living with HIV.” Leerink's Geoffrey Porges and Bradley Canino call the treatment "one of the most important products in our revenue outlook for Gilead." They explain why: [We] forecast the first sales of the combination in Q1 from the US and Q3 from Europe.

  • Bloomberg12 days ago

    The Hepatitis Drug Market Is Worse Than Wall Street Realizes

    Analysts haven't gotten the message, but some drugmakers have.

  • The 5 Best M&A Deals of 2017 (So Far!)
    Zacks13 days ago

    The 5 Best M&A Deals of 2017 (So Far!)

    Over the past few years, consolidation has become an important trend in nearly every major global industry. To celebrate this, we've compiled our list of the most important M&As of 2017!

  • Will Gilead & AbbVie Benefit from Merck's Decision to Drop Two HCV Programs?
    Zacks13 days ago

    Will Gilead & AbbVie Benefit from Merck's Decision to Drop Two HCV Programs?

    With Merck (MRK) discontinuing the development of two HCV candidates, here's a look at what to expect from the remaining key players in the HCV market.

  • Barrons.com14 days ago

    Bluebird Bio: So Much for That Gilead Boost

    When Gilead Sciences (GILD) announced its acquisition of Kite Pharma (KITE), every company that had exposure to CAR-T --a type of cancer therapy that could allow for the creation of personalized drugs--got ...

  • Merck Drops Two HCV Combination Programs Amid Competition
    Zacks14 days ago

    Merck Drops Two HCV Combination Programs Amid Competition

    Merck (MRK) is discontinuing the development of two of its hepatitis C (HCV) programs - MK-3682B and MK-3682C - as the HCV market is becoming extremely crowded.

  • MarketWatch15 days ago

    Merck Hepatitis C exit could lift the space’s two remaining drugmakers

    “This, in a nutshell, changes everything,” one Wall Street analyst said.

  • Two patients show the promise of a historic treatment, with an equally historic price tag
    CNBC17 days ago

    Two patients show the promise of a historic treatment, with an equally historic price tag

    Kymriah is among a new wave of therapies that use a patient's own cells as medicine. But this historic treatment comes with a historic price.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes